zanidatamab zovodotin,trastuzumab deruxtecan
daiichi sankyo,astrazeneca,zymeworks
['mbc', 't-dxd', 'zw49', '$zyme']
1/n #esmo22 zw49 $zyme seems well tolerated, however, unexpected is the alopecia ( the linker would need a closer look). the dose needs to be increased (t-dxd is dosed much higher). the efficacy data (orr, dcr) at 2.5 mg/kg 3qw in 3l mbc are very weak,
Biotech Investor, Former Scientist, M.D., Tweets since October 2019